Grants and Contributions:
Title:
COVID-19 Rapid Response: Preclinical studies for safety and efficacy of lung-directed Site-Specific Immunomodulator (SSI) in COVID-19 relevant animal model
Agreement Number:
961167
Agreement Value:
$2,780,109.00
Agreement Date:
Dec 1, 2020 - Aug 31, 2022
Description:
This project will provide proof-of-concept evidence for the safety and efficacy for the prophylactic and therapeutic use of a lung-directed immunomodulator, to prevent serious COVID-19 infection.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Burnaby, British Columbia, CA V5G 4X4
Reference Number:
172-2020-2021-Q3-961167
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
842333817
Recipient Type:
For-profit organization
Additional Information:
This agreement has been amended 1 time(s). The total amended value is -160,372 dollars.
Amendment Date
Aug 30, 2022
Recipient's Legal Name:
Qu Biologics Inc.
Federal Riding Name:
Burnaby South
Federal Riding Number:
59003
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
541710
Amendments: